Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 3 - What They Never Told You

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

Pfizer (PFE): Pre-Earnings Strategies

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.

StockNews.com

Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?

As Pfizer (PFE) navigates a post-pandemic world with a shifting focus away from COVID-related products, what should investors expect from this pharma giant? Let’s look at its financial metrics to know more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Inc. (PFE) vs. Taro Pharmaceutical (TARO) - Betting on Which Pharma Stock Will Have Q4 Dominance

The pharmaceutical industry’s prospects are driven by the rising occurrence of chronic diseases coupled with the adoption of cutting-edge technology. In this context, which company among the two major industry players, Pfizer Inc. (PFE) and Taro Pharmaceutical (TARO) are going to dominate the fourth quarter? Let’s find out….

StockNews.com

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

StockNews.com

Is Pfizer (PFE) a Stock to Buy Following Its Q3 Earnings?

Pfizer (PFE) faces weakening demand for its COVID products, resulting in a topline decline in the third quarter. Should investors consider buying the stock now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Pfizer Inc. (PFE) – Buy or Hold Analysis on This Pharma Stock

Leading pharma company Pfizer (PFE) is struggling to recover from waning Covid vaccine demand and is eyeing cost-cutting measures. So, is the stock worth buying? Read on.

StockNews.com

3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa Pharmaceuticals (KNSA) might be worth adding to one’s watchlist for value. Read on.

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

StockNews.com

Looking for a Value Investment? Check out These 3 Pharma Stocks

The pharmaceutical industry looks well-positioned for long-term growth. Therefore, fundamentally strong Merck & Co (MRK), Pfizer (PFE), and Lipocine (LPCN) could be ideal value investments now. Keep reading.

StockNews.com

Should Value Investors Go After Pfizer (PFE)?

Pfizer Inc (PFE), currently trading at a discount, is charting a path to enduring expansion via strategic acquisitions and the introduction of novel products. Despite this drive, recent financial results lack significant optimism. Given this scenario, should investors invest in PFE? Let’s look at its financial metrics to gauge its…

StockNews.com

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Zenger

Elderly Nursing Home Residents Denied Life-Saving COVID Treatment, Study Finds

Inadequate use of antiviral medication led to avoidable mortality, with Paxlovid underutilized

StockNews.com

Should Value Investors Watch Pfizer (PFE)?

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Zenger

Global Pharma Has $700B For M&A And Investments – From AI To Obesity Drugs

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments

Tribune News Service

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharma Stocks Every Investor Should Know

The pharma sector is poised to witness significant growth due to the widespread adoption of generic medicines and emerging technologies. Therefore, fundamentally strong pharma stocks Pfizer (PFE), Sanofi (SNY), and Spero Therapeutics (SPRO) might be solid buys. Read on.

Zenger

Pfizer Warns Of Potential Pediatric Antibiotic Shortage Amid Surge In Syphilis Infections

Pfizer Inc cautions about potential supply shortages for pediatric Bicillin L-A, an antibiotic for syphilis treatment.

StockNews.com

Should You Buy Into Pfizer (PFE) Today?

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

Tribune News Service

COVID kills 1 person every 4 minutes as vaccine rates fall

After more than three years, the global COVID-19 emergency is officially over. Yet it’s still killing at least one person every four minutes and questions on how to deal with the virus remain unanswered, putting vulnerable people and undervaccinated countries at risk.

StockNews.com

Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

StockNews.com

2 of the Best Biotech Stocks to Buy This Month

The biotech industry is growing thanks to breakthrough advancements and government initiatives. Furthermore, during market downturns, the biotech sector is more defensive than others. So, fundamentally sound biotech stocks Pfizer (PFE) and AstraZeneca (AZN) could be worth buying. Read on.

StockNews.com

3 Low P/E Stocks Gearing Up to Rebound This Year

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Moderna Inc

124 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.